"Pseudomonas aeruginosa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection.
| Descriptor ID |
D011550
|
| MeSH Number(s) |
B03.440.400.425.625.625.100 B03.660.250.580.590.050
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pseudomonas aeruginosa".
Below are MeSH descriptors whose meaning is more specific than "Pseudomonas aeruginosa".
This graph shows the total number of publications written about "Pseudomonas aeruginosa" by people in this website by year, and whether "Pseudomonas aeruginosa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 4 | 0 | 4 |
| 2003 | 5 | 3 | 8 |
| 2004 | 5 | 0 | 5 |
| 2005 | 9 | 3 | 12 |
| 2006 | 3 | 2 | 5 |
| 2007 | 4 | 0 | 4 |
| 2008 | 4 | 3 | 7 |
| 2009 | 2 | 0 | 2 |
| 2010 | 5 | 2 | 7 |
| 2011 | 5 | 3 | 8 |
| 2012 | 4 | 0 | 4 |
| 2013 | 1 | 3 | 4 |
| 2014 | 3 | 1 | 4 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 5 | 1 | 6 |
| 2018 | 1 | 0 | 1 |
| 2019 | 6 | 2 | 8 |
| 2020 | 3 | 1 | 4 |
| 2021 | 4 | 4 | 8 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 5 | 6 |
| 2024 | 3 | 0 | 3 |
| 2025 | 2 | 2 | 4 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pseudomonas aeruginosa" by people in Profiles.
-
Whole-genome profiling of antimicrobial resistance and virulence determinants in extensively-drug resistant Pseudomonas aeruginosa isolates causing ventilator associated pneumonia in Egypt. BMC Infect Dis. 2026 Jul 20; 26(1).
-
Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers. Antimicrob Agents Chemother. 2026 06 03; 70(6):e0026826.
-
Successful Bacteriophage Treatment of a Recalcitrant Intra-Abdominal Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa in a 2-Year-Old Child. J Pediatr. 2026 Apr; 291:115005.
-
Biofilm disruption and gene expression alteration by phages against multidrug-resistant Pseudomonas aeruginosa. Can J Microbiol. 2026 Jan 01; 72:1-12.
-
Multidrug-resistant gram-negative organisms: A primer on mechanisms of resistance and emerging therapies for the non-infectious diseases clinician. Am J Med Sci. 2026 02; 371(2):140-150.
-
The antibacterial effect of human adipose-derived stem cells on LL-37-resistant bacteria. PLoS One. 2025; 20(10):e0333647.
-
Antimicrobial Resistance Patterns in Pseudomonas Aeruginosa Isolated from Chronic Suppurative Otitis Media. J Coll Physicians Surg Pak. 2025 Jul; 35(7):866-870.
-
Rose Bengal photodynamic antimicrobial therapy as an adjunct treatment for Pseudomonas aeruginosa infectious necrotizing scleritis. Photodiagnosis Photodyn Ther. 2025 Jun; 53:104575.
-
Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2025 05; 25(5):574-584.
-
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin. Antimicrob Agents Chemother. 2024 08 07; 68(8):e0012724.